ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tocilizumab

Also written as “Tocilizumab”, “tocilizumab [RoActemra/Actemra]” and “MRA(Tocilizumab)”.

Its studies are mostly in Arthritis, Rheumatoid · Arthritis, Juvenile · COVID-19 · Scleroderma, Systemic · Giant Cell Arteritis, led by 9 companies.

Drug pageTocilizumab: every studyMany companies study it; this page follows only the 129 they lead. All 336 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 9, 2009129 company-led studies, 4 open or runningNext primary completion: Jul 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche1162 open or runningphase 4since Nov 9, 2009Mar 25, 2005Jul 30, 2027phase 2 · NCT04524871
Bio-Thera Solutionsits history only30 open or runningphase 3since Jan 22, 2019Jul 12, 2018none ahead
Bristol-Myers Squibbits history only22 open or runningphase 3since Jan 9, 2026Feb 7, 2025Nov 14, 2028phase 3 · NCT07335562
Fresenius Kabiits history only20 open or runningphase 3since Aug 11, 2020Aug 30, 2017none ahead
JW Pharmaceuticalits history only20 open or runningphase 3since Sep 29, 2010Sep 29, 2010none ahead
Beijing VDJBioits history only10 open or runningphase 2since Jul 11, 2023Jul 11, 2023none ahead
Biogenits history only10 open or runningphase 1since Feb 8, 2024Feb 8, 2024none ahead
Celltrionits history only10 open or runningphase 3since Feb 2, 2023Feb 2, 2023none ahead
Mycenax Biotechits history only10 open or runningphase 1since Apr 11, 2018Apr 11, 2018none ahead

Also a collaborator on its studies: Gilead Sciences, Pfizer, Adagene, Tempest Therapeutics, NiKang Therapeutics and Immune-Onc Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Mar 18, 2011.

  1. Feb 11, 2016Phase 4 study in Arthritis, RheumatoidNCT02682823 · 91 enrolled · United States
  2. May 15, 2017Phase 3 study in Arthritis, RheumatoidNCT03155347 · 340 enrolled · China
  3. Jun 9, 2017Phase 2 study in Pancreatic AdenocarcinomaNCT03193190 · 341 enrolled · United States, Germany, Japan and more
  4. Jun 27, 2017Phase 3 study in Giant Cell ArteritisNCT03202368 · 3 enrolled · France
  5. Sep 21, 2017Phase 4 study in Arthritis, JuvenileNCT03301883 · 62 enrolled · China
  6. Jan 30, 2018Phase 2 study in Breast NeoplasmsNCT03424005 · 1,132 planned · United States, Australia, France and more
  7. Mar 8, 2019Phase 2 study in Carcinoma, Transitional CellNCT03869190 · 272 enrolled · United States, France, Greece and more
  8. Apr 19, 2019Phase 1 study in Giant Cell ArteritisNCT03923738 · 24 enrolled · Switzerland
  9. Mar 23, 2020Phase 3 study in COVID-19 PneumoniaNCT04320615 · 452 enrolled · United States, Canada, Denmark and more
  10. Apr 21, 2020Phase 2 study in COVID-19 PneumoniaNCT04363736 · 97 enrolled · United States
  11. Apr 29, 2020Phase 3 study in COVID-19 PneumoniaNCT04372186 · 377 enrolled · United States, Brazil, Kenya and more
  12. May 28, 2020Phase 3 study in COVID-19 PneumoniaNCT04409262 · 649 enrolled · United States, Brazil, Russian Federation and more
  13. Aug 21, 2020Phase 2 study in Advanced Liver CancersNCT04524871 · 518 enrolled · United States, China, France and more
  14. Dec 16, 2021Phase 1 study in COVID-19NCT05164133 · 2 enrolled · United States, Brazil, Croatia and more

Ahead

  1. Jul 30, 2027Primary completion: phase 2 study in Advanced Liver CancersNCT04524871
  2. Sep 30, 2030Primary completion: phase 2 study in Breast NeoplasmsNCT03424005

TargetBeta

IL6R →read by rule
“A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity”NCIt, by rule
“Interleukin-6 receptor alpha subunit inhibitor”ChEMBL 37, by rule

Other programs on IL6R

ProgramCompanyFurthest phaseStudies
sarilumabruleSanofiphase 427

Studies

The newest 60 of 116 Hoffmann-La Roche leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT05164133COVID-19 · United States, Brazil, Croatia and more1CompletedMar 27, 20242
NCT04524871Advanced Liver Cancers · United States, China, France and more2Active, not recruitingJul 30, 2027518
NCT04409262COVID-19 Pneumonia · United States, Brazil, Russian Federation and more3CompletedFeb 1, 2021649
NCT04372186COVID-19 Pneumonia · United States, Brazil, Kenya and more3CompletedAug 18, 2020377
NCT04363736COVID-19 Pneumonia · United States2CompletedAug 12, 202097
NCT04320615COVID-19 Pneumonia · United States, Canada, Denmark and more3CompletedJun 24, 2020452
NCT03923738Giant Cell Arteritis · Switzerland1CompletedNov 12, 202024
NCT03869190Carcinoma, Transitional Cell · United States, France, Greece and more2TerminatedOct 8, 2025272
NCT03424005Breast Neoplasms · United States, Australia, France and more2RecruitingSep 30, 20301,132
NCT03301883Arthritis, Juvenile · China4CompletedSep 4, 202162
NCT03202368Giant Cell Arteritis · France3CompletedAug 21, 20193
NCT03193190Pancreatic Adenocarcinoma · United States, Germany, Japan and more2CompletedFeb 27, 2025341
NCT03155347Arthritis, Rheumatoid · China3CompletedAug 8, 2022340
NCT02682823Arthritis, Rheumatoid · United States4CompletedJul 29, 201691
NCT02678988Healthy Volunteer · United States1CompletedJun 2016189
NCT02573012Arthritis, Rheumatoid · France, Germany, Italy and more4CompletedFeb 9, 2018314
NCT02453256Scleroderma, Systemic · United States, Argentina, Belgium and more3CompletedJan 15, 2018212
NCT02336048Leukemia, Lymphocytic, Chronic, B-Cell · Israel, Italy, Latvia and more1TerminatedSep 21, 201838
NCT02165345Arthritis, Juvenile · United States, Argentina, Australia and more1CompletedNov 24, 202182
NCT02046616Arthritis, Rheumatoid · Denmark, Finland, Norway and more3CompletedSep 13, 2016133
NCT02046603Arthritis, Rheumatoid · United Kingdom3CompletedAug 4, 2016162
NCT02031471Arthritis, Rheumatoid · Belgium, Luxembourg3CompletedSep 201557
NCT02011334Arthritis, Rheumatoid · Argentina, Brazil, Colombia and more3CompletedOct 2016285
NCT02010216Arthritis, Rheumatoid · Kazakhstan4CompletedJul 201023
NCT02001987Arthritis, Rheumatoid · France3CompletedDec 2015139
NCT01991990Healthy Volunteer · United Kingdom4CompletedDec 201418
NCT01987479Arthritis, Rheumatoid · Netherlands3CompletedMay 26, 2016150
NCT01995201Arthritis, Rheumatoid · Ireland, Portugal, Spain3CompletedJul 2015401
NCT01988012Arthritis, Rheumatoid · Israel3CompletedJul 2015100
NCT01951170Arthritis, Rheumatoid · Australia3CompletedAug 201552
NCT01941940Arthritis, Rheumatoid · Italy3CompletedSep 9, 2015227
NCT01941095Arthritis, Rheumatoid · Greece3CompletedJul 10, 2016100
NCT01904292Arthritis, Juvenile · United States, Argentina, Australia and more1CompletedJun 13, 201752
NCT01904279Arthritis, Juvenile · United States, Argentina, Australia and more1CompletedMay 201652
NCT01878318Arthritis, Rheumatoid4WithdrawnJun 20150
NCT01791153Giant Cell Arteritis · United States, Belgium, Canada and more3CompletedApr 11, 2016251
NCT01772316Arthritis, Rheumatoid · Spain3CompletedMay 201547
NCT01734382Arthritis, Juvenile · United States, Argentina, Canada and more4CompletedOct 9, 201935
NCT01734993Arthritis, Rheumatoid · France3CompletedSep 201511
NCT01730456Arthritis, Rheumatoid · North Macedonia3CompletedMay 201513
NCT01727986Arthritis, Juvenile · Brazil3CompletedNov 201511
NCT01715831Arthritis, Rheumatoid · Brazil4CompletedJun 6, 201626
NCT01673919Arthritis, Juvenile · France3CompletedJan 20147
NCT01668966Arthritis, Rheumatoid · Brazil3CompletedMay 11, 201623
NCT01667471Arthritis, Juvenile · Germany3CompletedAug 20136
NCT01665430Arthritis, Rheumatoid · Poland3TerminatedFeb 201538
NCT01664598Arthritis, Rheumatoid · Russian Federation3CompletedJun 201549
NCT01662063Arthritis, Rheumatoid · United States, Puerto Rico3CompletedApr 2014218
NCT01655381Arthritis, Rheumatoid · France3CompletedJul 201515
NCT01649804Arthritis, Rheumatoid · Hungary3CompletedDec 201412
NCT01610791Arthritis, Rheumatoid · Morocco3CompletedAug 2011121
NCT01575769Arthritis, Juvenile · Poland, Russian Federation3TerminatedDec 3, 201341
NCT01587989Arthritis, Rheumatoid · Austria3CompletedFeb 201477
NCT01532869Scleroderma, Systemic · United States, Canada, France and more3CompletedJan 201487
NCT01468077Arthritis, Rheumatoid · Denmark, Iceland2CompletedSep 201347
NCT01455701Arthritis, Juvenile · United States, Argentina, Belgium and more1CompletedJul 28, 201611
NCT01399697Arthritis, Rheumatoid · Spain4CompletedMay 2014261
NCT01353859Arthritis, Rheumatoid · Indonesia3CompletedJul 201239
NCT01347983Arthritis, Rheumatoid · Taiwan3CompletedMar 201372
NCT01332994Arthritis, Rheumatoid · Germany3CompletedFeb 2014519

How it is read

Names in the registry

  • “Tocilizumab”, 54 entries
  • “tocilizumab [RoActemra/Actemra]”, 47 entries
  • “MRA(Tocilizumab)”, 11 entries
  • “tocilizumab”, 6 entries
  • “MSB11456”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.